REDWOOD CITY, Calif.,
Aug. 23, 2012 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that Richard King, President and CEO, will present a
corporate overview at the following investor conferences:
2012 Southern California Investor Conference
Date: Thursday, August 30,
2012 at 1:30 p.m. PDT
(4:30 p.m. EDT)
Location: Marriott-Newport Beach, Newport Beach, Calif.
Stifel Nicolaus Healthcare Conference 2012
Date: Thursday, September 6,
2012 at 9:10 a.m. EDT
(6:10 a.m. PDT)
Location: The Four Seasons Hotel, Boston, Mass.
Rodman & Renshaw Annual Global Investment Conference
Date: Tuesday, September 11,
2012 at 9:35 a.m. EDT
(6:35 a.m. PDT)
Location: The Waldorf Astoria, New
York City, N.Y.
All presentations will be webcast live and can be accessed
through the investor relations page at www.acelrx.com. For
those not available to listen to the live broadcast, a replay of
the presentations will be archived and available through
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, the ARX-01 Sufentanil
NanoTab PCA System, which is currently in Phase 3 clinical
development, is designed to solve the problems associated with
post-operative intravenous patient-controlled analgesia which has
been shown to cause harm to patients following surgery because of
the side effects of morphine, the invasive IV route of delivery and
the inherent potential for programming and delivery errors
associated with the complexity of infusion pumps. AcelRx has
two additional product candidates which have completed Phase 2
clinical development: ARX-02 for the treatment of cancer
breakthrough pain, and ARX-03 for mild sedation, anxiety reduction
and pain relief for patients undergoing painful procedures in a
physician's office. AcelRx plans to initiate a Phase 2 study,
pending protocol approval, for a fourth product candidate, ARX-04,
a sufentanil formulation for the treatment of moderate-to-severe
acute pain, funded through a grant from USAMRMC. For
additional information about AcelRx's clinical programs please
visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to planned or
anticipated future clinical development of AcelRx Pharmaceuticals'
product candidates, and the therapeutic potential of AcelRx
Pharmaceuticals' product candidates. These forward-looking
statements are based on AcelRx Pharmaceuticals' current
expectations and inherently involve significant risks and
uncertainties. AcelRx Pharmaceuticals' actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to:
the success, cost and timing of AcelRx Pharmaceuticals' product
development activities and clinical trials; the market potential
for its product candidates; and other risks detailed in the "Risk
Factors" and elsewhere in AcelRx Pharmaceuticals' U.S. Securities
and Exchange Commission filings, including its Quarterly Report on
Form 10-Q for the three months ended June
30, 2012. AcelRx Pharmaceuticals undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.